← SynDRA
LUVIXASERTIB
SynDRA canonical compound SYN0039891 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | TTK |
|---|
| Mechanism of action | dual specificity protein kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- dual specificity protein kinase inhibitor
- TTK INHIBITOR
Cross-references
Synonyms
- CFI-402257
- CFI402257
- CPD 24
- CFI 402257
- CHEMBL4442392
- CHEMBL4469414
- SCHEMBL16729234
- SCHEMBL17182976
- SCHEMBL17190272
- SCHEMBL22046104
- SCHEMBL22875551
- BCP31204
- EX-A2577
- BDBM50512456
- BDBM50533120
- NSC800888
- ZINC669678971
- CS-6527
- NSC-800888
- SB19839
- AK685452
- HY-101340
- J3.619.525H
- N-cyclopropyl-4-(7-((((1r,3r)-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(pyridin-3-yloxy)pyrazolo[1,5-a]pyrimidin-3-yl)-2-methylbenzamide
- N-cyclopropyl-4-[7-[(3-hydroxy-3-methylcyclobutyl)methylamino]-5-pyridin-3-yloxypyrazolo[1,5-a]pyrimidin-3-yl]-2-methylbenzamide
Look up LUVIXASERTIB in the interactive SynDRA portal →